CORRAL-AF: LAmbre Plus Device in NVAF

Randomised, open-label trial in Atrial fibrillation (AFib) (3 arms). Primary endpoints: Composite of time to first occurrence of stroke, cardiovascular death, or clinically relevant major or non-major bleeding events at 5 years, Composite of time to first occurrence of ischemic stroke or systemic embolism at 5 years and 1 more. Planned start Jun 2024; status: withdrawn.